Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026
Same author

Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8<sup>+</sup> T cell fate.

Research square·2026
Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026
Same author

NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroids.

bioRxiv : the preprint server for biology·2026
Same author

Publisher Correction: Atlas-guided discovery of transcription factors for T cell programming.

Nature·2026
Same author

The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 20, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Blocking PD-1 in cancer immunotherapy.

Gianpietro Dotti1

  • 1Baylor College of Medicine, USA.

Blood
|August 22, 2009
PubMed
Summary

The programmed cell death protein 1 (PD-1) pathway is a key mechanism tumors use to evade the immune system. High PD-1 expression on T cells in blood cancers and solid tumors correlates with reduced T-cell function.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The programmed cell death protein 1 (PD-1) pathway is increasingly recognized as a critical mechanism by which tumors evade immune surveillance.
  • This pathway involves interactions that can suppress T-cell activity, hindering the immune system's ability to eliminate cancer cells.

Discussion:

  • Three independent studies published in Blood highlight the significant role of PD-1 in malignancies.
  • These studies consistently found high expression of PD-1 on tumor-specific cytotoxic T lymphocytes (CTLs) across various hematologic and nonhematologic cancers.
  • This elevated PD-1 expression is directly linked to impaired T-cell function, suggesting a mechanism of immune suppression within the tumor microenvironment.

Key Insights:

  • PD-1 is highly expressed on cytotoxic T lymphocytes targeting tumors in both blood cancers and solid tumors.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

  • High PD-1 expression on these T cells is associated with diminished their cytotoxic function.
  • This finding underscores PD-1's role as a major immune checkpoint in cancer.

    • Outlook:

    • Further research into the PD-1 pathway could lead to novel immunotherapeutic strategies.
    • Targeting PD-1 may restore T-cell function and enhance anti-tumor immunity.
    • Understanding PD-1's role is crucial for developing effective cancer treatments.